All In Biotech

Drug Trial Radar · NCT04006808

A Study to Test GlaxoSmithKline's (GSK) Candidate Vaccine-GSK1437173A for Prevention of Shingles in Children With Kidney Transplant

A Reactogenicity, Safety and Immunogenicity Study of GSK's Paediatric Herpes Zoster Subunit Candidate Vaccine (PED-HZ/su) GSK143713A in Immunocompromised Paediatric Renal Transplant Recipients

Last checked: Nov 20, 2026Latest source record: Feb 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 184 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

184

Planned (sponsor's estimate)

Start

Oct 25, 2019

Primary completion

May 1, 2026

Study completion Mar 31, 2027

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Jul 5, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 1 year, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the reactogenicity, safety and immunogenicity of 2 doses of PED-HZ/su, GSK's vaccine candidate for the prevention of Herpes Zoster (HZ) in immunocompromised paediatric renal transplant recipients aged 1-17 years

Conditions

  • Herpes Zoster

Interventions

  • PED-HZ/suBiological

    GSK's candidate vaccine- PED-HZ/su. is administered intramuscularly in the deltoid of the non-dominant arm, on a two-dose schedule in the two investigational groups.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of subjects from the interventional groups, with solicited local adverse events (AEs)Time frame: Within 7 days after each vaccination (vaccines administered on day 1 and month 1)
  2. Number of subjects from the interventional groups, with solicited general AEsTime frame: Within 7 days after each vaccination (vaccines administered on day 1 and month 1)
  3. Number of subjects from the control groups with solicited general symptomsTime frame: Within 7 days after Visit Day 1
  4. Number of subjects from the control groups with solicited general symptomsTime frame: Within 7 days after Visit Month 1
  5. Number of subjects from the interventional groups with unsolicited AEs after each vaccinationTime frame: Within 30 days after each vaccination (vaccines administered on day 1 and month 1)
  6. Number of subjects from the control groups with unsolicited symptomsTime frame: Within 30 days after Visit Day 1
  7. Number of subjects from the control groups with unsolicited symptomsTime frame: Within 30 days after Visit Month 1
  8. Number of subjects with serious adverse events (SAEs), potential immune mediated diseases (pIMDs) and biopsy confirmed renal allograft rejection.Time frame: From Visit Day 1 up to Visit Month 2
  9. Number of subjects from the interventional groups with seizuresTime frame: Within 30 days after each vaccination (vaccines administered on day 1 and month 1)
  10. Number of subjects from the non-interventional groups with seizuresTime frame: Within 30 days after Visit Day 1
  11. Number of subjects from the non-interventional groups with seizuresTime frame: Within 30 days after Visit Month 1
  12. Number of subjects from the interventional groups with generalized convulsive seizuresTime frame: Within 7 days after each vaccination (vaccines administered on day 1 and month 1)
  13. Number of subjects from the non-interventional groups with generalized convulsive seizuresTime frame: Within 7 days after Visit Day 1
  14. Number of subjects from the non-interventional groups with generalized convulsive seizuresTime frame: Within 7 days after Visit Month 1
  15. Percentage of subjects with Anti-gE antibody concentrations in terms of Geometric Mean Concentrations (GMCs)Time frame: At Month 2 (one-month post-dose 2)

Locations

31 sites in 6 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Brussels, Belgium · Recruiting

  • GSK Investigational Site

    Ghent, Belgium · Recruiting

  • GSK Investigational Site

    Leuven, Belgium · Recruiting

  • GSK Investigational Site

    Liège, Belgium · Recruiting

  • GSK Investigational Site

    Bordeaux, France · Recruiting

  • GSK Investigational Site

    Lille, France · Recruiting

  • GSK Investigational Site

    Marseille, France · Recruiting

  • GSK Investigational Site

    Montpellier, France · Recruiting

  • GSK Investigational Site

    Nantes, France · Withdrawn

  • GSK Investigational Site

    Paris, France · Recruiting

  • GSK Investigational Site

    Paris, France · Recruiting

  • GSK Investigational Site

    Toulouse, France · Recruiting

  • GSK Investigational Site

    Genova, Italy · Completed

  • GSK Investigational Site

    Milan, Italy · Recruiting

  • GSK Investigational Site

    Padova, Italy · Recruiting

  • GSK Investigational Site

    Roma, Italy · Recruiting

  • GSK Investigational Site

    Torino, Italy · Recruiting

  • GSK Investigational Site

    Gdansk, Poland · Recruiting

  • GSK Investigational Site

    BaracaldoVizcaya, Spain · Recruiting

  • GSK Investigational Site

    Espluges de Llobregat, Spain · Completed

  • GSK Investigational Site

    HebrOn, Spain · Recruiting

  • GSK Investigational Site

    Madrid, Spain · Recruiting

  • GSK Investigational Site

    Madrid, Spain · Recruiting

  • GSK Investigational Site

    Seville, Spain · Recruiting

  • GSK Investigational Site

    Birmingham, United Kingdom · Completed

  • GSK Investigational Site

    Cardiff, United Kingdom · Completed

  • GSK Investigational Site

    Glasgow Strathclyde, United Kingdom · Recruiting

  • GSK Investigational Site

    London, United Kingdom · Recruiting

  • GSK Investigational Site

    Manchester, United Kingdom · Recruiting

  • GSK Investigational Site

    Nottingham, United Kingdom · Recruiting

  • GSK Investigational Site

    Southampton, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.